Prescrire Int. 2008 Jun;17(95):103-4.
The papillomavirus 16, 18 vaccine, like the papillomavirus 6, 11, 16, 18 vaccine, reduces the risk of high-grade cervical dysplasia due to all viral genotypes by about 40% in young women who are not yet infected at the time of vaccination. The vaccine does not seem to provoke any serious adverse effects, but there is no proof that it reduces the risk of cancer.
人乳头瘤病毒16、18疫苗，与6、11、16、18型人乳头瘤病毒疫苗一样，在接种时未感染的年轻女性中，可将所有病毒基因型导致的高级别宫颈发育异常风险降低约40%。该疫苗似乎不会引发任何严重不良反应，但尚无证据表明其能降低患癌风险。
